Cancer Grant

Recipients

2019 Recipients

Judith

Agudo,

Ph.D.

2018

Boston,

MA

Dana-Farber Cancer Institute/Harvard Medical School

Developing a Novel Tool Called the Jedi Mouse to Study T Cell Function

Dr. Judith Agudo joined the Dana-Farber Cancer Institute as a Principal Investigator in 2017. After obtaining her Ph.D. at University Autonomous of Barcelona, she was awarded a Fulbright scholarship in 2010 to perform her postdoc training in the Immunology Institute in the Icahn School of Medicine at Mount Sinai. During her postdoctoral training she developed a novel tool called the Jedi mouse to study T cell function. This unique technology has allowed her to elucidate mechanisms controlling immune surveillance of tissue-resident stem cells and cancer stem cells.

Dr. Agudo has developed a pre-clinical model of breast cancer dissemination and dormancy in bone marrow. With help from the Mary Kay Foundation grant, Dr. Agudo is using her novel Jedi technology to investigate immune-therapy based approaches to achieve eradication of dormant breast cancer disseminated cells before they grow metastatic tumors.

Charles

Caskey,

Ph.D.

2018

Nashville,

TN

Vanderbilt University Medical Center

Enhancing Breast Cancer Immunotherapy with Microbubbles

Dr. Charles Caskey studies diagnostic and therapeutic uses of ultrasound. He received his Ph.D. in biomedical engineering from the University of California at Davis.

Dr. Caskey is using the Mary Kay Foundation grant to study how focused ultrasound therapy could potentially be an ideal helper for immunotherapy. Immunotherapy has had a profound impact on cancer treatment by mobilizing the body's natural disease-fighting mechanisms to fight cancer. Despite promising results in specific cancers (e.g., skin and bladder), reliable response in breast cancer remains challenging. A successful outcome of Dr. Caskey’s research would expand the use of immunotherapy to breast cancers that are not currently responsive to this potentially lifesaving treatment.

Lan

Coffman,

Ph.D.

2018

Pittsburgh,

PA

UPMC Hillman Cancer Center

Investigating the Role of Carcinoma-Associated Mesenchymal Stem Cells in Ovarian Cancer Metastasis

Dr. Lan Coffman attended Wake Forest University School of Medicine when obtaining her Ph.D. and M.D. Her research focuses on the ovarian cancer microenvironment, understanding and targeting the cancer supporting stromal tissues which are critical to the survival, growth and spread of ovarian cancer.

With help from the Mary Kay Foundation grant, Dr. Coffman is studying the supportive environment or “soil” where cancer cell “seeds” grow in order to metastasize. This “soil” provides vital nutrients and protects the cancer cell “seeds” from being destroyed.  One critical cell within this “soil” is the carcinoma-associated mesenchymal stem cell (CA-MSC) which acts like fertilizer supporting cancer cell survival, growth and spread. The goal of Dr. Coffman’s research is to understand how CA-MSCs promote ovarian cancer metastasis and to develop strategies to block CA-MSC cancer cell interactions as a new way to fight ovarian cancer.

R.

Juan

Cubillos-Ruiz,

Ph.D.

2018

New York,

NY

Weill Cornell Medicine

Targeting Syk-driven ER Stress Responses to Enhance Ovarian Cancer Immunotherapies

Dr. Juan R. Cubillos-Ruiz obtained his postdoc at Weill Cornell Medicine. His lab aims to understand how Endoplasmic Reticulum stress responses sculpt immune cell function in health and disease. Dr. Cubillos-Ruiz is the scientific founder and advisor of Quentis Therapeutics, a biotechnology company pursuing next-generation immuno-oncology research and drug development.

With help from the Mary Kay Foundation grant, Dr. Cubillos-Ruiz is aiming to understand how ovarian tumors cause dysfunction of immune cells, and exploit this knowledge to develop more potent immunotherapies. His project aims to use selective drugs to disable sensors of stress in immune cells and render them resistant to the unfavorable conditions within tumors. Dr. Cubillos-Ruiz and his team will develop a new approach to overcome the limitations of existing immune-based treatments. By exploring these novel approaches to cancer immunotherapy, they aim to strengthen the capacity of the patient’s immune system to eliminate ovarian cancer.

David

DeNardo,

Ph.D.

2018

St. Louis,

MO

Washington University in St. Louis

Overcoming Stromal Barriers to Immunotherapeutic Efficacy

Dr. David DeNardo obtained his Ph.D. in Cell Biology at Baylor College of Medicine and performed his postdoc work at University of California, San Francisco. His research interests include immune response, metastasis, breast cancer and pancreatic cancer.

Dr. DeNardo is studying the mechanisms by which senescent stromal cells (which are found in high numbers in breast cancer tissues at diagnosis) thwart immunotherapy. He also plans to test the ability of clinically available agents that inactivate cellular senescence to overcome resistance to immunotherapy. With help from the Mary Kay Foundation grant, Dr. DeNardo and his team’s goal is to provide optimized immunotherapeutic strategies that would be highly effective, even in heavily pre-treated metastatic breast cancer patients.

Gianpietro

Dotti,

M.D.

2018

Chapel Hill,

NC

University of North Carolina Lineberger Comprehensive Cancer Center

Natural Killer T Cells (NKTs) Specific for Triple Negative Breast Cancer

Dr. Gianpietro Dotti studies immunotherapy strategies to treat patients with hematologic malignancies, including lymphomas and leukemia, and solid tumors. A significant focus of Dr. Dotti’s research is the development of strategies of utilizing engineered T cells to overcome immune suppressive mechanisms of the tumor microenvironment.

Dr. Dotti has had success in treating patients with hematological malignancies by using their own immune cells modified with a chimeric molecule that eliminates tumor cells. He and his team are now focused on extending this approach to solid tumors such as neuroblastoma, glioblastoma, ovarian cancer, pancreatic cancer and triple negative breast cancer. These solid tumors including TNBC remain very difficult to treat. With help from the Mary Kay Foundation grant, Dr. Dotti intends to use a specific type of immune cells that are characterized by a high capacity to reach the tumor and to eliminate not only the tumor cells but also other cells that are helping the tumor to grow.

M.

Amy

Fowler,

M.D., Ph.D.

2018

Madison,

WI

University of Wisconsin-Madison

Impact of Activating Mutations in the Estrogen Receptor Alpha Gene on Quantitative 18F-Fluoroestradiol Imaging of Breast Cancer

Dr. Amy Fowler is an Assistant Professor at the University of Wisconsin School of Medicine and Public Health. She specializes in diagnostic radiology and breast imaging including mammography, ultrasound, and MRI. Her research focuses on molecular imaging for precision medicine to improve outcomes for patients with breast cancer.

With the Mary Kay Foundation grant, Dr. Fowler is studying ways to predict and identify drug resistance early in order to start alternative therapies in a timely manner, as generally many anti-estrogen therapies have initial success but patients then develop drug resistance. The purpose of Dr. Fowler’s project is to test whether mutated forms of the protein that binds estrogen and drives tumor growth (termed estrogen receptor alpha or ER) lose the ability to bind FES (18F-fluoroestradiol), which is a radiotracer used to visualize and quantify tumor ER expression when patients undergo a positron emission tomography (PET) scan. The results from her work will better define the patient population in which FES PET imaging yields the most accurate results for support of U.S. Food and Drug Administration approval of this technique to tailor individual patient treatment plans.

Roger

Lo,

M.D., Ph.D.

2018

Los Angeles,

CA

UCLA Jonsson Comprehensive Cancer Center

Exploiting Drug-Addiction in MAPK Inhibitor-Resistant Ovarian Cancer with BRCAness

Dr. Roger Lo is an accomplished physician-scientist widely recognized for his work in understanding treatment-resistant melanoma. His laboratory’s research focus is on genomic, epigenomic and immunologic factors that shape the cancer’s evolution on molecularly targeted therapies and/or immune checkpoint inhibitors. He has led groundbreaking research into resistance mechanisms against a promising class of drugs known as BRAF inhibitors and discovered ways to block multiple resistance routes and shrink tumors in people with advanced disease. Approximately 50 percent of advanced melanoma tumors, which often metastasize throughout the body, are driven to spread by the presence of BRAF mutations and therefore treatable by BRAF inhibitors. Dr. Lo’s group is also working to tackle resistance mechanisms in additional subsets of melanoma in order to test novel therapies for these patients.

With the Mary Kay Foundation grant, Dr. Lo is studying a "one-two punch" method in attacking cancer cells. He is testing whether ovarian cancers with specific and concurrent molecular features would most optimally respond to a treatment that includes exploiting cancer medicine addiction, weakening DNA in cancer cells and ultimately killing them.

Melanie H. Cobb, Ph.D. and Ankita Jaykumar, Ph.D.

2018

Dallas,

TX

University of Texas – Southwestern Medical Center

The Role of WNK1/OSR1 in Breast Cancer Cell Migration

Dr. Melanie H. Cobb attended Washington University in St. Louis to obtain her Ph.D. and did her postdoc work at the Albert Einstein College of Medicine in New York. Her interests are protein kinases in cellular regulatory mechanisms.

Dr. Cobb is using the Mary Kay Foundation grant to help determine if a particular signaling pathway (WNK1/OSR1 pathway) could be a potential therapeutic target in breast cancer. The gene WNK1 was recently identified as a “signature gene” expressed in a particularly aggressive class of breast cancers called basal-like breast cancers. Basal-like breast cancers grow rapidly, tend to affect younger patients, and have the worst prognosis of all breast cancers. Dr. Cobb, along with lead researcher Dr. Ankita Jaykumar and team, will test the effect of specific inhibitors on cell migration and survival in both traditional breast cancer cell culture and in tumor tissue embedded in 3D Matrigel. This will provide evidence of the potential of the WNK1/OSR1 pathway as a therapeutic target in breast cancer.

Theresa Li-Yun Chang, Ph.D. and Mark Einstein, M.D., M.S.

2018

Newark.

NJ

Rutgers New Jersey Medical School

Identifying Mucosal Immune Determinants for Cervical Carcinogenesis

Dr. Theresa Li-Yun Chang attended New York University to obtain her Ph.D. and did her postdoc at Yale University. Her lab is interested in the role of innate immunity in sexual transmitted infection-mediated enhancement of HIV infection, and HIV infection of human peritoneal macrophages.

Dr. Mark Einstein is a Gynecologic Oncologist and clinician-scientist. His primary research interests focus on the pathogenesis, therapy, and prevention of HPV-associated diseases as well as early drug development. He has developed and lead numerous multi-institutional clinical trials for many rare gynecologic diseases.  Currently, as an Assistant Dean at Rutgers New Jersey Medical School, his role has taken on a much broader context across many disciplines at NJMS.

Dr. Chang and Dr. Einstein are collaborating to study cervical cancer in women. Infection with a cancer-causing form of human papillomavirus (HPV) is required for the development of cervical cancer. While most women easily clear an HPV infection through their immune system, some women cannot, and if not detected with screening and treated early, precancerous lesions may become cervical cancer over time. Cervical cancer develops as a result of the immune tug-of-war in the cervical microenvironment. The Mary Kay Foundation grant will help Drs. Chang and Einstein determine the specific immune functions that are impaired in women with cervical cancer and HIV.

Their research will expand knowledge of how cervical cancer develops in women, especially vulnerable populations such as women infected with HIV. It will also contribute to the development of early diagnostic tools to prevent cervical cancer and novel immune-based cancer therapies for effective treatment of this deadly disease.

Alexei

Tulin,

Ph.D.

2018

Grand Forks,

ND

University of North Dakota

New Class of Non-NAD-like PARP-1 Inhibitors: An Effective Strategy Targeting Drug-resistant Breast Cancer

Dr. Alexei Tulin received his Ph.D. in Epigenetics from Moscow State University. His long-term interest is exploring how cells can undergo rapid, local and reversible chromatin reprogramming.

With help from the Mary Kay Foundation grant, Dr. Tulin is studying how Poly (ADP-ribose) polymerase 1 (PARP-1)-regulated signaling contributes to the start and progression of various human malignancies. Several recently concluded studies show clear promise of PARP-1 inhibitors for the treatment of breast cancer patients. But this treatment is limited. To address these limitations, Dr. Tulin and his lab have developed a new class of PARP-1 inhibitors with the overall objective of developing effective anti-cancer therapeutics by examining the antitumor activity of the newly created PARP-1 inhibitors.

Lixing

Yang,

Ph.D.

2018

Chicago,

IL

University of Chicago

Neoantigens Formed by Gene Fusion and Intron Exonization in Breast Cancer

Dr. Lixing Yang received his Ph.D. from the University of Georgia and his postdoc at Harvard Medical School. He is interested in the evolutionary process of cancer and genetic alterations in various forms that accumulate over a long period of time to form cancer cells. He also studies genomic rearrangements and how they affect and change DNA structure.

Dr. Yang is using the Mary Kay Foundation grant to study breast cancer. Currently, there is no immunotherapy therapy available for breast cancer. The hope of this study is to be able to detect patient specific neoantigens and better predict which patients are more likely to respond to immunotherapy.

Carmen

Bergom,

M.D., Ph.D.

2017

Milwaukee,

WI

Medical College of Wisconsin

Identifying Genetic Factors that Decrease Side Effects and Enhance the Efficacy of Breast Cancer Radiation

M.

Susann

Brady-Kalnay

2017

Cleveland,

OH

Case Western Reserve University School of Medicine

PTPμ as a targeting agent for ultrasound-enhanced treatment of ovarian cancer

Sidi

Chen

2017

New Haven,

CT

Yale University

Identifying novel non-coding biomarkers for ovarian cancer metastasis

Anthony

Faber

2017

Richmond,

VA

Virginia Commonwealth University

A major cause of HER2i resistance in HER2-amplified breast cancer and a therapeutic combination to overcome it

Katherine

Fuh,

M.D., Ph.D.

2017

St. Louis,

MO

Washington University

Predictive Kinome for Treatment of Chemo resistant Ovarian Cancer

Melissa

Herbst-Kralovetz,

Ph.D.

2017

Phoenix,

AZ

University of Arizona, Phoenix

Elucidating the Genital Microbiome and Local Immune Microenvironment in Endometrial Cancer Patients

Manabu

Kurokawa,

Ph.D.

2017

Hanover,

NH

Geisel School of Medicine at Dartmouth

Targeting the fatty acid transporter CD36 in HER2 positive breast cancer

Michael

Pacold

2017

New York,

NY

New York University School of Medicine

Targeting serine metabolism in breast cancer

Ali

Shilatifard

2017

Chicago,

IL

Northwestern University Feinberg School of Medicine

Therapeutic targeting of SET1B/COMPASS pathway in treating triplenegative breast cancer

Fiona

Simpkins

2017

Philadelphia,

PA

University of Pennsylvania

Circumventing drug resistance in CCNE1 amplified ovarian cancer

Jiangbin

Ye

2017

Stanford,

CA

Stanford University

Targeting serine and one-carbon unit metabolism in metastatic breast cancer

Qing

Zhang

2017

Chapel Hill,

NC

University of North Carolina at Chapel Hill

Hairless (HR) as a Novel Therapeutic Target in Basal-Like Breast Cancer

Ross

Cagan,

M.D.

2016

New York,

NY

Icahn School of Medicine at Mount Sinai

Drosophila Models of Triple Negative Breast Cancer as a Platform to Identify Novel Therapeutics

Ronald

Chandler,

Ph.D.

2016

East Lansing,

MI

Michigan State University, College of Human Medicine

SWI/SNF chromatin remodeling and Pl3-kinase pathway crosstalk mechanisms in ovarian cancer

E.

Jack

Dixon,

M.D.

2016

La Jolla

CA

University of California San Diego

DYRK2, a novel therapeutic target for Triple-Negative Breast Cancer

Hui

Feng,

Ph.D.

2016

Boston,

MA

Boston University School of Medicine

Targeting Elevated S1P1 Signaling as a Novel Therapeutic Approach for Triple-Negative Breast Cancer

Michael

Flister,

M.D.

2016

Milwaukee

WI

West Medical College of Wisconsin

Role of Tumor-Host Crosstalk in Genetic Evolutionary Response of Breast Cancer

Hamid

Mirzaei,

M.D.

2016

Dallas,

TX

UT Southwestern Medical Center

Developing a high-resolution SRM-based diagnostic platform for breast cancer subclinical diagnosis and personalized therapy

E.

Raymond

Moellering,

M.D.

2016

Chicago,

IL

University of Chicago Comprehensive Cancer Center

Precision imaging diagnostics to detect and target metastatic progression in breast and ovarian cancer

G.

Richard

Moore,

M.D.

2016

Rochester,

NY

University of Rochester

The Role of HE4 in Immunity, Chemotaxis and Immune Dysfunction in Ovarian Cancer

Aydogan

Ozcan,

M.D.

2016

Los Angeles,

CA

UCLA David Geffen School of Medicine

Automated Pap smear Testing using a Field-Portable and Cost-effective Lensfree Computational Microscopy Platform

T.

Richard

Pomerantz,

Ph.D.

2016

Philadelphia,

PA

Temple University School of Medicine

Targeting DNA Polymerase for Precision Medicine in BRCA Deficient Cancers

B.

Erinn

Rankin,

M.D.

2016

Palo Alto,

CA

Stanford

Hypoxic Signaling in Tumor Metastasis: Molecular Mechanisms and Targeted Therapy

A.

David

Spiegel,

M.D.

2016

New Haven,

CT

Yale University

Enhancing Immune Recognition of Breast Cancer Using Small Molecules

Nikhil

Wagle

M.D.

2016

Boston,

MA

Harvard Medical School

Elucidating Mechanisms of Intrinsic and Acquired Resistance to Combined ER and CDK4/6 Inhibition in Metastatic Breast Cancer

Mekhail

Anwar,

Ph.D.

2015

San Francisco,

CA

University of California, San Francisco

The Development of a Microfabricated Fluorescent Imager for Real-Time, Intraoperative Imaging of Microscopic Residual Disease in Breast Cancer

A.

Lewis

Chodosh,

Ph.D.

2015

Philadelphia,

PA

Trustees of University of Pennsylvania

Mechanisms of breast cancer dormancy and recurrence

Roisin

Connolly,

Ph.D.

2015

Baltimore,

MD

Johns Hopkins Univ. SOM

Harnessing the immune system to treat breast cancer: Novel mechanisms of resistance and treatment strategies

M.

Brooke

Emerling,

Ph.D.

2015

New York,

NY

Joan & Sanford I. Weill Med. College of Cornell University

Targeting p53 mutant breast cancers through inhibition of the Phosphatidylinositol-5 Phosphate 4 Kinases

Steven

Frisch,

Ph.D.

2015

Morgantown,

WV

West Virginia University Research Corp.

Suppression of Breast Cancer Recurrence

R.

Michael

Green,

Ph.D.

2015

Wocester,

MA

University of Massachusetts Medical School

Understanding and Predicting Therapeutic Responsiveness in Ovarian Cancer

J.

Edward

Gunther,

M.D.

2015

Hershey,

PA

Penn State College of Medicine

Genetic Dissection of Breast Cancer Metastasis Using Time-Stamped Transposon Mutagenesis

Michael

Karin,

Ph.D.

2015

La Jolla,

CA

University of California, San Diego

Tackling Breast Cancer Metastasis by Targeting Ubiquitination-Mediated Signaling Pathways

W.

Todd

Miller,

Ph.D.

2015

Lebanon,

NH

Geisel School of Medicine at Dartmouth

Mechanisims underlying doormancy in ER+ breast cancer

Dohun

Pyeon,

Ph.D.

2015

Aurora,

CO

University of Colorado Denver

Targeing Chemokine Expression in the Tumor Microenvironment to Suppress Cervical Cancer Progression

Ana

Rosa

Risques,

Ph.D.

2015

Seattle,

WA

University of Washington

Early detection of ovarian cancer by ultra-sensitive sequencing of Pap smear DNA

J.

Daniel

Siegwart,

Ph.D.

2015

Dallas,

TX

UT Southwestern Medical Center

Dendritic Lipid Nanoparticle (DLNP)-mediated miRNA Delivery to Treat Ovarian Cancer

Rong

Xu,

Ph.D.

2015

Cleveland,

OH

Case Western Reserve University Medical School

Combining a novel computational drug repositioning approach with clinical and biological testing for rapid epithelial ovarian cancer druge discovery

P.

Thomas

Ahern,

Ph.D.

2014

Burlington,

VT

University of Vermont College of Medicine

Predictive biomarkers of breast tumor response to statin therapy

K.

Carey

Anders,

Ph.D.

2014

Chapel Hill,

NC

University of North Carolina-Chapel Hill SOM

Targeting The P13K and MEK Pathways in Triple Negative Breast Cancer Brain Metastases

A.

Luis

Diaz,

M.D.

2014

Baltimore,

MD

Johns Hopkins University

A molecular pap smear for the detection of ovarian and endometrial cancers

Mohit

Jain,

Ph.D.

2014

La Jolla,

CA

University of California, San Diego

Targeting Cancer-Specific Metabolic Activity for Breast Cancer Therapy

A.

Carol

Lange,

Ph.D.

2014

Minneapolis,

MN

University of Minnesota

PTK6 Drives Metastasis in Therapy-Resistant Triple-Negative Breast Cancer

Yi

Li,

Ph.D.

2014

Houston,

TX

Baylor College of Medicine

Intermittent rusolitinib treatment for preveiton of breast cancer in nulliparous women

Laurie

Littlepage

Ph.D.

2014

South Ben,

IN

University of Notre Dame

Overcoming Breast Cancer Chemoresistance Using ZNF217 as a Prognostic Marker and Therapeutic Target

Vivek

Mittal,

Ph.D.

2014

New York,

NY

Joan & Sanford I. Weill Medical College of Cornell University

Pharmacological targeting of the Polycomb Frepressive Complex 2 impairs breast cancer metastasis

Melissa

Skala,

Ph.D.

2014

Nashville,

TN

Vanderbilt University

A New Paradigm for Drug Development and Treatment Planning in Breast Cancer

Yihong

Wan,

Ph.D.

2014

Dallas,

TX

UT Southwestern Medical Center

A Novel Strategy to Inhibit Bone Metastasis of Breast Cancer

de la

Adam

Zerda

Ph.D.

2014

Palo Alto,

CA

Stanford University

MOZART: A New Breast Cancer Duagnostic Technology for Single Cell Imaging In Vivo

Peter

Zhou,

Ph.D.

2014

Lexington,

KY

University of Kentucky

Dissectingthe critical Functions of theDub3-Snail Axis in Basal-like Breast Cancer

K.

David

Ann,

Ph.D.

2013

Duarte,

CA

City of Hope

Targeting Arginine Dependency, a Metabolic Achilles' Heel for Breast Cancer

S.

Alexander

Brodsky,

Ph.D.

2013

Providence,

RI

Brown University

New Approaches to Target Mevalonate Biosynthesis for Ovarian Cancer

Kathleen

Cho,

M.D.

2013

Ann Arbor,

MI

The University of Michigan

Examining falopian tube origin of high grade serous "ovarian" carcinoma

Dipanjan

Chowdhury,

Ph.D.

2013

Boston,

MA

Dana-Farber Cancer Institute

MicroRnas as a Molecular Basis for Defective Homologous Recombination in Epithelial Ovarian Cancer

Analisa

DiFeo,

Ph.D.

2013

Cleveland,

OH

Case Western Reserve University Sch. of Medicine

Single Agent Dual Inhibition of the AKT and ERK Signaling Pathway for the Treatment of Ovarian Cancer

J.

Andrew

Ewald,

Ph.D.

2013

Baltimore,

MD

Johns Hopkins University

Basal marker+ cancer cells lead collective invasion and dissemination across multiple subtypes of breast cancer

Liza

Makowski,

Ph.D.

2013

Chapel Hill,

NC

University of North Caroline at Chapel Hill

Reversing carcinogenic effect of obesity on basal-like breast cancer

G.

Michael

Rosenfeld,

M.D.

2013

La Jolla,

CA

University of California, San Diego

Reprogramming Breast Cancer Cells

Y.

Joy

Wu

Ph.D.

2013

Stanford,

CA

Stanford University Sch. of Med.

Effects of Parahyroid Hormone on the Breast Cancer Metastatic Niche in Bone

M.

Gerburg

Wulf,

Ph.D.

2013

Boston,

MA

Beth Israel Deaconess Medical Center

Use of P13Kinase inhibitors to improve the Outcomes of Antineoplastic Treatments for Breast Cancer

Jacob

Berlin,

Ph.D.

2012

Duarte,

CA

City of Hope

Stem Cell-Mediated Targeted Therapy for Triple Negative Breast Cencer

L. M.

Alfred

Bothwell,

Ph.D.

2012

New Haven,

CT

Yale University

Modeling of Human Immune System Interaction with Breast Tumors and Treatments in Mice

A.

Rolf

Brekken,

Ph.D.

2012

Dallas,

TX

UT Southwestern Medical Center

ALK as a driver of breast cancer metastasis

C.

Eric

Chang,

Ph.D.

2012

Houston,

TX

Baylor College of Medicine

N-Ras as a key regulator and potential treatment target for basal-like breast cancer

R.

Gerald

Crabtree,

M.D.

2012

Stanford,

CA

Stanford University

Targeting Ovarian Cancer via Cooperative Oncogene Interactions

H.

Paloma

Giangrande,

Ph.D.

2012

Iowa City,

IA

University of Iowa

Multifunctional RNA-based Reagents for the Treatment of Ovarian Cancer

K.

Andrew

Godwin,

Ph.D.

2012

Kansas City,

KS

University of Kansas Medical Center

High-Throughput Microfluidic Exosome Profiling Platform for Early Detection of Ovarian Cancer

William

Hahn,

Ph.D.

2012

Boston,

MA

Dana-Farber Cancer Institute

Genomic Characterization of Brain Metastases from Breast Cancer

David

Sherr,

Ph.D.

2012

Boston,

MA

Trustees of Boton University, BUMC

A Novel AhR-Targeted Therapeutic for Triple Negative and Chemo-Resistant Breast Cancers

Barry

Sleckman,

Ph.D.

2012

St. Louis,

MO

Washington University

Identification of Novel DNA double strand break repair targeting therapeutics for the treatment of breast cancer

LuZhe

Sun,

Ph.D.

2012

San Antonio,

TX

The University of Texas Health Science Center at San Antonio

Bisphenol A and Breast Cancer -- Effect on Mammary Stem Cell and its Niche

J.

John

Turchi,

Ph.D.

2012

Indianapolis,

IN

Indiana University

Rational, biology-based combination therapy for the treatment of ovarian cancer

L.

Deric

Wheeler,

Ph.D.

2012

Madison,

WI

Board of Regents of the University of WI System

Targeting nuclear EGFR: Strategies for improving cetuximab therapy in triple-negative breast cancer

Emily

Bernstein,

Ph.D.

2011

New York,

NY

Mount Sinai School of Medicine

Identifying Epigenetic Drivers of Breast Cancer

L.

Kenneth

Bost,

Ph.D.

2011

Charlotte,

NC

University of North Carolina at Charlotte

A viral infection that exacerbates breast cancer mestastasis

J.

Martina

Cannon,

Ph.D.

2011

Little,

AR

University of Arkansas

Dendritic cell activation of therapeutic Th17 responses against ovarian cancer

G.

Jeanette

Cook,

M.D.

2011

Chapel Hill,

NC

The University of North Carolinal at Chapel Hill

Predicting genone instability in breast cancer

Yan

Dong,

Ph.D.

2011

New Orleans,

LA

Tulane University School of Medicine

Improving the therapeutic outcome for triple-negative breast cancer by restoring normal function to mutant p53

R.

Kevin

Kozak,

Ph.D.

2011

Madison,

WI

University of Wisconsin School of Medicine U Public Health

Rational Molecular Multi-targeting in Hormone Receptor-Positive Breast Cancer

Ruth

Lupu,

Ph.D.

2011

Rochester,

MN

Mayo Clinic

Fatty acid Synthase (FASN): Molecular Target for Breast Cancer Therapy

David

Lyden,

Ph.D.

2011

New York,

NY

Joan & Sanford I. Weill Medical of Cornell University

The role of bone marrow-derived progenitor cells and tumor emboli-derived exosomes in malignant progression of IBC

Sanaz

Memarzadeh,

Ph.D.

2011

Los Angeles,

CA

Regents of the University of California, Los Angeles

Mechanisims and predictors of response to progesterone therapy in endometrial carcinoma

W.

Gray

Pearson,

Ph.D.

2011

Dallas,

TX

UT Southwestern Medical Center

Investigating the non-cell autonomous regulation of breast cancer metastasis

Thomas

Szyperski,

Ph.D.

2011

Buffalo,

NY

University at Buffalo Foundation Services

Non-invasive diagnosis of early state ovarian cancer by 1H-NMR of blood serum

Zeng-Quan

Yang,

Ph.D.

2011

Detroit,

MI

Karmanos Cancer Institute

Targeting histone demethylases as a theerapeutic-strateby in basal breast cancer

Richard

Baer,

Ph.D.

2010

New York,

NY

Columbia University Medical Center

Which functions of BRCA1 suppress breast cancer:

E.

Mark

Burkard,

Ph.D.

2010

Madison,

WI

University of Wisconsin- Madison

Identifying synthetic lethal approaches targeting polyploidy in human breast cancer

Ronny

Drapkin,

Ph.D.

2010

Boston,

MA

Dana-Farber Cancer Institute

Defining the role of the fallopian tube secretory epithelial cell in the pathogenesis of serous ovanian carcinoma

Yan

Dong,

Ph.D.

2011

New Orleans,

LA

Tulane University School of Medicine

Improving the therapeutic outcome for triple-negative breast cancer by restoring normal function to mutant p53

Kevin

R.

Kozak,

Ph.D.

2011

Madison,

WI

University of Wisconsin School of Medicine U Public Health

Rational Molecular Multi-targeting in Hormone Receptor-Positive Breast Cancer

Ruth

Lupu,

Ph.D.

2011

Rochester,

MN

Mayo Clinic

Fatty acid Synthase (FASN): Molecular Target for Breast Cancer Therapy

David

Lyden,

Ph.D.

2011

New York,

NY

Joan & Sanford I. Weill Medical of Cornell University

The role of bone marrow-derived progenitor cells and tumor emboli-derived exosomes in malignant progression of IBC

Sanaz

Memarzadeh,

Ph.D.

2011

Los Angeles,

CA

Regents of the University of California, Los Angeles

Mechanisims and predictors of response to progesterone therapy in endometrial carcinoma

Gray

W.

Pearson,

Ph.D.

2011

Dallas,

TX

UT Southwestern Medical Center

Investigating the non-cell autonomous regulation of breast cancer metastasis

Thomas

Szyperski,

Ph.D.

2011

Buffalo,

NY

University at Buffalo Foundation Services

Non-invasive diagnosis of early state ovarian cancer by 1H-NMR of blood serum

Zeng-Quan

Yang,

Ph.D.

2011

Detroit,

MI

Karmanos Cancer Institute

Targeting histone demethylases as a theerapeutic-strateby in basal breast cancer

Richard

Baer,

Ph.D.

2010

New York,

NY

Columbia University Medical Center

Which functions of BRCA1 suppress breast cancer:

Mark

E.

Burkard,

Ph.D.

2010

Madison,

WI

University of Wisconsin- Madison

Identifying synthetic lethal approaches targeting polyploidy in human breast cancer

Ronny

Drapkin,

Ph.D.

2010

Boston,

MA

Dana-Farber Cancer Institute

Defining the role of the fallopian tube secretory epithelial cell in the pathogenesis of serous ovanian carcinoma

Edward

Gunther,

M.D.

2010

Hershey,

PA

Pennsylvania State College of Medicine

Dissecting Mammary Cell Lineage-specific Signaling Pathway

Richard

N.

Kitsis,

M.D.

2010

Bronx,

NY

Albert Einstein College of Medicine of Yeshiva University

Mechanistic Role of Necrosis - Not Apoptosis - in Breast Cancer

Lawrence

Lum,

Ph.D.

2010

Dallas,

TX

UT Southwestern Medical Center

Targeting the cancer stem cell compartment in breast and cervical cancer using novel tankyrase inhibitors

Martina

M.

Matzuk,

Ph.D.

2010

Houston,

TX

Baylor College of Medicine

Novel microRNA Therapies for Ovarian Cancer

Rita

Nahta,

Ph.D.

2010

Atlanta,

GA

Emory University

Growth Differentiation Factor 15, a novel mediator of trastuzumab resistance in HER2-overexpressing breast cancer

Roel

Nusse,

Ph.D.

2010

Stanford,

CA

Stanford University

Genes for self-renewal of normal and tumor breast stem cells

Sandra

Ryeom,

Ph.D.

2010

Philadelphia,

PA

University of Pennsylvania School of Medicine

Role of the Platelet Angiogenic Proteome in Cervical Cancer

Frank

Slack,

Ph.D.

2010

New Haven,

CT

Yale University

A microRNA binding site mutation in KRAS and risk of hereditary breast and ovarian cancer

Elizabeth

Swisher,

M.D.

2010

Seattle,

WA

University of Washington

BRCA1/2 Restoration as a Predictor in a GOG Clinical Trial for Recurrent Ovarian Carcinoma

Angelique

W.

Whitehurst,

Ph.D.

2010

Chapel Hill,

NC

The University of North Carolina at Chapel

Defining a Funcational Signature of Chemosensitivity in Ovarian Cancer Subtypes

Eric

J.

Brown,

Ph.D.

2009

Philadelphia,

PA

University of Pennsylvania

Treatment of ovarian and breast cancers through partial inhibition of the DNA replication checkpoint.

Viyakrishna

K.

Gadi,

M.D., Ph.D.

2009

Seattle,

WA

Fred Hutchinson Cancer Research Center

Fetal Microchimerism in Breast Cancer

Paloma

H.

Giangrande,

Ph.D.

2009

Iowa City,

IA

The University of Iowa

Multifunctional Aptamer-siRNA Chimeras Targeting EphA2 Expressing Breast Cancers

Kevin

A.

Janes,

Ph.D.

2009

Charlottesville,

VA

The Rector and Visitors of the University of Virginia

Mechanism of a TGFBR-JUND single cell dichotomy and its role in breast tumorigenesis

Paul

F.

Lambert

Ph.D.

2009

Madison,

WI

The Board of Regents of the Universtiy of Wisconsin System

A New Therapy for Cervical Cancer: Preclinical Studies

Mark

Moasser,

M.D.

2009

San Francisco,

CA

University of California, San Francisco

Breaking the HER3 barrier in the treatment of HER2-amplified breast cancer

Lynne

Regan,

Ph.D.

2009

New Haven,

CT

Yale University

Development of a Novel Class of Hsp90 Inhibitors as anti-Cancer Therapeutics

Julie

Schwarz,

M.D., Ph.D.

2009

St. Louis,

MO

Washington University

Targeting the premetastatic niche in cervical cancer

Philip

W.

Shaul,

M.D.

2009

Dallas,

TX

Univ. of Texas Southwesten Medical Center

Breast cancer modulation by 27-hydroxycholesterol, the first identifed endogenous SERM

Jose

M.

Silva,

Ph.D.

2009

New York,

NY

Columbia University

Genetic synthetic lethality: Genetics approaches for personalized breast cancer therapy

Thomas

Westbrook,

Ph.D.

2009

Houston,

TX

Baylor College of Medicine

Discovering therapeutic targets for breast cancer with new technologies

Jing

Yang,

Ph.D.

2009

La Jolla,

CA

University of California, San Diego

Dissecting the transcription network in breast tumor metastasis

Binhua

Zhou,

Ph.D.

2009

Lexington,

KY

University of Kentucky School of Medicine

Dissecting the dysregulaiton of epithelial-mesenchymal transition at breast cancer metastasis

Nita

Ahuja,

M.D.

2008

Baltimore,

MD

John Hopkins University

Molecular Staging of Breast Cancer Using Methylation Profiles

Steven

J.

Altschuler,

Ph.D.

2008

Dallas,

TX

UT Southwest Medical Center

Relating Ovarian Cancer Cell Phenotypes to Drug Sensitivities

James

Basilion,

Ph.D.

2008

Cleveland,

OH

Case Western Reserve University

Molecular imaging for ex vivo identification of tumor margin infiltrates in resected breast cancers

Brian

P.

Ceresa,

Ph.D.

2008

Oklahoma City,

OK

University of Oklahoma Health Sciences Center

HPV16 E5 Mediated Cell Fusion in Oncogenesis

Vincent

L.

Cryns,

M.D.

2008

Chicago,

IL

Northwestern University

Cancer stem cell-targeted therapies for breast cancer

Ekaterina

Dadachova,

Ph.D.

2008

Bronx,

NY

Albert Einstein College of Medicine

Targeting viral antigens with radiolabeled antibodies as a novel approach to treatment of cervical cancer

Daniela

Dinulescu,

Ph.D.

2008

Boston,

MA

Brigham and Women's Hospital, Harvard Medical School

Chemoresistance to therapy in ovarian cancer: role of cancer stem cells

Nathanael

S.

Gray,

Ph.D.

2008

Boston,

MA

Dana-Farber Cancer Institute

Pharmacological validation of FGFR as a target for the treatment of breast cancer

Roger

A.

Greenberg,

M.D., Ph.D.

2008

Philadelphia,

PA

University of Pennsylvania

Systematic identification of breast cancer susceptibility gene candidates within the BRCA1 tumor suppressor network

Rong

Li,

Ph.D.

2008

San Antonio,

TX

University of Texas Health Science Center at San Antonio

Adipose Aromatase Expression and Breast Cancer

Hannah

M.

Linden,

M.D.

2008

Seattle,

WA

University of Washington

Quantitative in Vivo Pharmacodynamics of Breast Cancer Endocrine Therapy using PET Estrogen Receptor Imaging

M.

Peter

Marinkovich,

M.D.

2008

Stanford,

CA

Stanford University School of Medicine

Tumor specific Laminin precursor domains in cervical carcinoma

John

I.

Risinger,

Ph.D.

2008

Macon,

GA

Mercer University

Characterization of the PSPHL gene preferentially overexpressed in gynecologic cancers from African Americans

Carol

L.

Rosenberg,

M.D.

2008

Boston,

MA

Boston University, BUMC

Copy Number Variation (CNV) in the initiation and progression of breast cancer

Pepper

Schedin

Ph.D.

2008

Aurora

CO

University of Colorado at Denver & Health Sciences Center

Role of Macrophages in the Metastatic Spread of Pregnancy-Associated Breast Cancer

Toni

M.

Antalis,

Ph.D.

2007

Baltimore,

MD

University of Maryland School of Medicine

Targeting Testisin as a Therapy for Ovarian Cancer

Ronald

J.

Buckanovich,

Ph.D.

2007

Ann Arbor,

MI

University of Michigan Cancer Center

CD14+ Vascular Leukocytes in Ovarian Cancer: Their Role in Angiogenesis, Prognosis and Therapeutics in Ovarian Cancer

Concepcion

R.

Diaz-Arrastia,

M.D.

2007

Galveston,

TX

University of Texas Medical Branch Galveston

Development of a Genomic Profile For The Progression of Cervical Intraepithelial Neoplasia

James

M.

Ford,

M.D.

2007

Stanford,

CA

Stanford University School of Medicine

A Novel Approach to Identify Chemoprevention Agents for BRCA1-associated Malignancies

Naomi

J.

Halas,

Ph.D.

2007

Houston,

TX

William Marsh Rice University

Nanoengineered Vectors for Targeted Delivery-Triggered Release of Gene Therapies for Ovarian, Breast, Cervical and Uterine Cancers

Patricia

J.

Keely,

Ph.D.

2007

Madison,

WI

University of Wisconsin at Madison

Analysis of Collagen Signatures to Determine Breast Cancer Progression in Clinical Samples

Ralph

P.

Mason,

Ph.D.

2007

Dallas,

TX

UT Southwestern Medical Center at Dallas

Predicting Treatment Response for Cervical Cancer: Non-Invasive Assessment Using BOLD MRI

Dan

Mercola,

M.D., Ph.D.

2007

Irvine,

CA

The Regents of the University of California

Development of a Diagnostic and Prognostic Test for Breast Cancer Based on DNA Methylation Signature

Ben

Ho

Park,

M.D.

2007

Baltimore,

MD

Johns Hopkins University

Mutational Somatic Cell Engineering for Breast Cancer Therapy

Antoni

Ribas,

M.D.

2007

Los Angeles,

CA

University of California Los Angeles (UCLA)

Immunotherapy of Cervical Cancer with Helper Dependent Adenovirus-Epstein-Barr Virus (HAD-EBV) Hybrid Vectors

Shiladitya

Sengupta,

Ph.D.

2007

Cambridge,

MA

Brigham and Women's Hospital

Polyvalent Nanoparticles for Targeting Breast Cancer

Dipali

Sharma,

Ph.D.

2007

Atlanta,

GA

Emory University

Adiponectin as a Protective Adipocytokine Against Leptin Signaling in Breast Tumorigenesis

Lin

Zhang,

Ph.D.

2007

Philadelphia,

PA

Trustees of the University of Pennsylvania

The Function of MicroRNA in Ovarian Cancer

Peter

D.

Adams,

Ph.D.

2006

Philadelphia,

PA

Institute for Cancer Research

Identification of novel genetic mutations in breast cancer that predict a favorable clinical response to the new anti-cancer therapeutic, SAHA

William

E.

Carson,

M.D.

2006

Columbus,

OH

The Ohio State University Research Foundation

A Phase 1 Trial of IL-21 in Combination with Weekly Paclitaxel and Trastuzumab in Patients with HER2-Positive Malignancies

Terry

Van

Dyke,

Ph.D.

2006

Chapel Hill,

NC

University of North Carolina at Chapel Hill

A mouse model of human ovarian cancer for mechanistic, diagnostic, and therapeutic discovery

Brittney-Shea

Herbert,

Ph.D.

2006

Indianapolis,

IN

Indiana University Cancer Center

Targeting Telomerase in Breast Cancer Stem Cells: Inhibition of Breast Tumor Recurrence and Metastasis

Maria

Jasin,

Ph.D.

2006

New York,

NY

Memorial Sloan-Kettering Cancer Center

DNA repair defects and ovarian cancer development

David

Kurnit,

M.D., Ph.D.

2006

Ann Arbor,

MI

The Regents of the University of Michigan

Detection of cervical dysplasia and cancer by MassARRAY detection of human papilloma virus

John

A.

Martignetti,

M.D., Ph.D.

2006

New York,

NY

Mount Sinai School of Medicine

Inhibition of KLF6-SV1: Targeting Ovarian Cancer Spread and Survival

Vered

Stearns,

M.D.

2006

Baltimore,

MD

Kimmel Cancer Center at Johns Hopkins

Intraductal therapy for breast cancer treatment and prevention

Sheila

A.

Stewart,

Ph.D.

2006

St. Louis,

MO

Washington University

Stromal Factors and Tumorigenesis

Theresa

V.

Strong,

Ph.D.

2006

Birmingham,

AL

The University of Alabama at Birmingham

The Role of Sp17 in Tumor Development

Muneesh

Tewari,

M.D., Ph.D.

2006

Seattle,

WA

Fred Hutchinson Cancer Research Center

An Integrated Functional Genomic Approach to Identify Cisplatin Resistance Determinants in Ovarian Cancer

Michael

A.

White,

Ph.D.

2006

Dallas,

TX

U.T. Southwestern Medical Center

Harnessing Genome-wide RNAi to Guide Rational Design of Combinatorial Chemotherapies Targeting Ovarian Cancer

Hua

Zhao,

Ph.D.

2006

Buffalo,

NY

Health Research, Inc.

Pharmocogenetic Profiles to Predict Response to Chemotherapy in Ovarian Cancer

Robert

Benezra,

Ph.D.

2005

New York,

NY

Memorial Sloan-Kettering Cancer Center

Targeted anti-angiogenic therapy with peptide conjugated antisense oligonucleotides (PCAOs)

Diego

H.

Castrillon,

M.D., Ph.D.

2005

Dallas,

TX

The University of Texas Southwestern Medical Center

Roles of FoxO Transcription Factors in Endometrial Cancer

William

Cliby,

M.D.

2005

Rochester,

MN

Mayo Clinic

ATR is a mutational target in endometrial cancers: opportunities for a novel therapeutic advantage

James

DiRenzo,

Ph.D.

2005

Hanover,

NH

Dartmouth Medical School

Evaluation of Genetic Pathways Underlying Stem Cell Renewal as Predictors of Early Malignancy in Breast Cancer

Suzanne

Fuqua,

Ph.D.

2005

Houston,

TX

Baylor College of Medicine

Dual Specificity Phosphatase 6 and Tamoxifen Resistance

Theresa

A.

Guise,

M.D.

2005

Charlottesville,

VA

University of Virginia, Division of Endocrinology

Inhibition of Breast Cancer Bone Metastasis with Anti-Hypoxic Treatment

Leaf

Huang,

Ph.D.

2005

Chapel Hill,

NC

University of North Carolina

Therapeutic Vaccine for Cervical Cancer

Michael

M.

Ouellette,

Ph.D.

2005

Omaha,

NE

University of Nebraska Medical Center

Novel Strategies for the Inhibition of Telomerase in Breast Cancer cells

Richard

Roden,

Ph.D.

2005

Baltimore,

MD

Johns Hopkins School of Medicine

Vaccination against cervical cancer

Toshiyasu

Taniguchi,

M.D., Ph.D.

2005

Seattle,

WA

Fred Hutchinson Cancer Research Center

Sensitization of Ovarian Cancer Cells to Chemotherapy by Modulating the Fanconi Anemia-BRCA Pathway

Richard

Bankert,

Ph.D.

2004

Buffalo,

NY

State University of New York at Buffalo

Breast Cancer Vaccine Designed to Eradicate Both Primary and Metastatic Tumors and Generate a Prolonged Anti-Tumor Immunity

Sharon

B.

Cantor,

Ph.D.

2004

Worcester,

MA

University of Massachusetts Medical School

BRCA1 Associated BACH1 Helicase as a Biomarker for Breast Cancer

Sudhansu

K.

Dey,

Ph.D.

2004

Nashville,

TN

Vanderbilt University Medical Center

Cyclooxygenase-1 is a Target for Ovarian Cancer Prevention and Treatment

Leif

W.

Ellisen,

Ph.D.

2004

Boston,

MA

The General Hospital Corporation

P53 Family Members in Refractory Breast Cancers

William

K.

Holloman,

Ph.D.

2004

New York,

NY

Weill Medical College of Cornell University

Novel Screen for BRCA2-deficiency Chemopreventive Drugs

Robert

B.

Jaffe,

M.D.

2004

San Francisco,

CA

UCSF Comprehensive Cancer Center

VEGF-Trap + Paclitaxel to Reduce Tumor Burden & Ascites in Ovarian Cancer

Alessandro

D.

Santin,

M.D.

2004

Little Rock,

AR

University of Arkansas for Medical Sciences

Therapy with Clostridium Perfringens Enterotoxin (CPE) for Chemotherapy Resistant Ovarian Cancer

Richard

Schlegel,

M.D., Ph.D.

2004

Washington,

DC

Georgetown University Medical School

A Topical Drug Treatment for Early Cervical Cancer

Victoria

L.

Seewaldt,

M.D.

2004

Durham,

NC

Duke University School of Medicine

Defining the Role of RARbeta2 and CBP in Mammary Hyperplasia: A Bench to Bedside Model of Breast Cancer Risk and Prevention

Ann

D.

Thor,

M.D.

2004

Aurora,

CO

The University of Colorado At Denver

Mechanism of E2 Activation by Thyroid Hormone in Breast Cancer Cells

Carlos

L.

Arteaga,

M.D.

2003

Nashville,

TN

Vanderbilt University Medical Center

Mechanisms of Resistance to Aromatase Inhibitors in Breast Cancer

George

Coukos,

M.D., Ph.D.

2003

Philadelphia,

PA

Trustees of the University of Pennsylvania

Immunotherapy of Ovarian Cancer

David

A.

Frank,

M.D., Ph.D.

2003

Boston,

MA

Dana-Farber Cancer Institute

STAT5 Isoforms in the Pathogenesis of Breast Cancer: Differential Effects of Nearly Identical Transcription Factors

Thomas

F.

Franke,

M.D., Ph.D.

2003

New York,

NY

Columbia University in the City of New York, Dept. of Pharmacology

Therapeutic Targets Downstream of AKT Kinases

Scott

Goode,

Ph.D.

2003

Houston,

TX

Baylor College of Medicine

Potent Suppressors of Tumorogenesis

2018 Recipients
homecausesgiveeventsblog
donate now